88
Participants
Start Date
October 27, 2019
Primary Completion Date
March 6, 2021
Study Completion Date
March 30, 2021
Continuous glucose monitoring
"Subjects enrolled will be randomized 1:1 to either receive a daily dosage of dapagliflozin 10 mg and 2000 mg metformin for 12 weeks or 2000 mg metformin. Patients who do not tolerate metformin at 2000mg dose will be downtitrated to 1500 mg daily. In case patients do not tolerate 1500 mg daily, they will be excluded.~Both groups will be monitored for 7 days using either iPro™ CGM system (Medtronic, Northridge, CA) or Dexcom G6 CGM (Dexcom Inc, San Diego, CA). Basal continuous glucose monitoring will start at week 1 (first visit), and removed at day 7 and final continuous glucose monitoring will start at week 11 and removed 7 days after (final visit)."
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán ''INCMNSZ'', Mexico City
Collaborators (1)
AstraZeneca
INDUSTRY
Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
OTHER